Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cadonilimab + Capecitabine + Oxaliplatin |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cadonilimab | AK-104|AK 104|AK104 | CTLA4 Antibody 33 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 134 | Cadonilimab is a bispecific antibody that targets CD274 (PD-L1) and CTLA-4, potentially resulting in enhanced anti-tumor immune response (PMID: 36872527). | |
| Capecitabine | Xeloda | R340 | Chemotherapy - Antimetabolite 14 | Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary). |
| Oxaliplatin | Eloxatin | Diaminocyclohexane Oxalatoplatinum | Chemotherapy - Platinum 7 | Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | gastric adenocarcinoma | predicted - sensitive | Cadonilimab + Capecitabine + Oxaliplatin | Phase III | Actionable | In a Phase III trial (COMPASSION-15), first-line combination therapy with Cadonilimab, Xeloda (capecitabine), and Eloxatin (oxaliplatin) demonstrated safety in CD274 (PD-L1)-positive (CPS >=5), ERBB2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma patients, and resulted in an improved median overall survival (15.3 vs 10.9 mo, HR=0.58) and median progression-free survival (6.9 vs 5.5 mo, HR=0.51) compared to placebo plus chemotherapy (PMID: 39843940; NCT05008783). | 39843940 |
| CD274 positive | gastroesophageal junction adenocarcinoma | predicted - sensitive | Cadonilimab + Capecitabine + Oxaliplatin | Phase III | Actionable | In a Phase III trial (COMPASSION-15), first-line combination therapy with Cadonilimab, Xeloda (capecitabine), and Eloxatin (oxaliplatin) demonstrated safety in CD274 (PD-L1)-positive (CPS >=5), ERBB2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma patients, and resulted in an improved median overall survival (15.3 vs 10.9 mo, HR=0.58) and median progression-free survival (6.9 vs 5.5 mo, HR=0.51) compared to placebo plus chemotherapy (PMID: 39843940; NCT05008783). | 39843940 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST